Care for adults with COVID-19: living guidelines from the National COVID-19 Clinical Evidence Taskforce.
Heath WhiteSteve J McDonaldBridget BarberJoshua DavisLucy BurrPriya NairSutapa MukherjeeBritta TendalJulian ElliottSteven McGloughlinTari TurnerPublished in: The Medical journal of Australia (2022)
The Taskforce currently recommends eight drug treatments for people with COVID-19 who do not require supplemental oxygen (inhaled corticosteroids, casirivimab/imdevimab, molnupiravir, nirmatrelvir/ritonavir, regdanvimab, remdesivir, sotrovimab, tixagevimab/cilgavimab) and six for those who require supplemental oxygen (systemic corticosteroids, remdesivir, tocilizumab, sarilumab, baricitinib, casirivimab/imdevimab). Based on evidence of their achieving no or only limited benefit, ten drug treatments or treatment combinations are not recommended; an additional 42 drug treatments should only be used in the context of randomised trials. Additional recommendations include support for the use of continuous positive airway pressure, prone positioning, and endotracheal intubation in patients whose condition is deteriorating, and prophylactic anticoagulation for preventing venous thromboembolism. The latest updates and full recommendations are available at www.covid19evidence.net.au.
Keyphrases
- coronavirus disease
- sars cov
- venous thromboembolism
- positive airway pressure
- obstructive sleep apnea
- clinical trial
- end stage renal disease
- quality improvement
- respiratory syndrome coronavirus
- clinical practice
- healthcare
- ejection fraction
- palliative care
- chronic kidney disease
- cardiac arrest
- newly diagnosed
- emergency department
- atrial fibrillation
- cystic fibrosis
- drug induced
- direct oral anticoagulants
- quantum dots
- pain management
- combination therapy